Pharmacology of ACE inhibitors versus at1 blockers

Canadian Journal of Cardiology

Volumn 16, Issue SUPPL. E, 2000, Pages

  Vaughan, Douglas ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Bradykinin; Fibrinolysis; Plasminogen activators

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ANIMAL; ARTERIOSCLEROSIS; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FIBRINOLYSIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIOSCLEROSIS; BLOOD PRESSURE; BRADYKININ; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; LOSARTAN; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; VASODILATION;

EID: 0034243411     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
2. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993;91:1453-8.
3. Fennessy PA, Campbell JH, Mendelsohn FAO, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996;23(Suppl 1):S30-2.
4. Kakinuma Y, Hama H, Sugiyama F, et al. Impaired blood-brain barrier function in angiotensinogen-deficient mice. Nat Med 1998;4:1078-80.
5. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515-20.
6. Brown NJ, Agirbasli MA, Williams OH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965-71.
7. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type I receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999;34:285-90.
8. Mugellini A, Zoppi A, Corradi L, et al. Effect of trandolapril and losartan on plasma PAI-1 and fibrinogen in hypertensive postmenopausal women. Am J Hypertens 1998;11:112A. (Abst)
9. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997;77:522-5.
10. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999;33:1431-5.
11. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92.
12. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
13. Anderson TJ, Overhiser RW, Haber H, Charbonneau F. A comparative study of four antihypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol 1998;31(Suppl A):327A. (Abst 1147-54)